VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Wednesday, December 31, 2025

Stock Comparison

Abbott Laboratories vs Bureau Veritas S.A.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Abbott Laboratories

ABT · New York Stock Exchange

Market cap (USD)$219.2B
SectorHealthcare
CountryUS
Data as of2025-12-30
Moat score
64/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Abbott Laboratories's moat claims, evidence, and risks.

View ABT analysis

Bureau Veritas S.A.

BVI · Euronext Paris

Market cap (USD)
SectorIndustrials
CountryFR
Data as of2025-12-28
Moat score
66/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Bureau Veritas S.A.'s moat claims, evidence, and risks.

View BVI analysis

Comparison highlights

  • Moat score gap: Bureau Veritas S.A. leads (66 / 100 vs 64 / 100 for Abbott Laboratories).
  • Segment focus: Abbott Laboratories has 7 segments (26.7% in Cardiovascular & Electrophysiology Devices); Bureau Veritas S.A. has 6 segments (29.3% in Buildings & Infrastructure).
  • Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
  • Moat breadth: Abbott Laboratories has 10 moat types across 3 domains; Bureau Veritas S.A. has 6 across 3.

Primary market context

Abbott Laboratories

Cardiovascular & Electrophysiology Devices

Market

Cardiovascular, electrophysiology, rhythm management, structural heart and heart failure devices

Geography

Global

Customer

Hospitals, ambulatory surgery centers, cardiologists/electrophysiologists

Role

Implantable device manufacturer

Revenue share

26.7%

Bureau Veritas S.A.

Buildings & Infrastructure

Market

Construction, buildings and infrastructure inspection/testing and project assurance

Geography

Global

Customer

Developers, contractors, infrastructure operators, public authorities

Role

Third-party testing/inspection and compliance verification across project lifecycle

Revenue share

29.3%

Side-by-side metrics

Abbott Laboratories
Bureau Veritas S.A.
Ticker / Exchange
ABT - New York Stock Exchange
BVI - Euronext Paris
Market cap (USD)
$219.2B
n/a
Sector
Healthcare
Industrials
HQ country
US
FR
Primary segment
Cardiovascular & Electrophysiology Devices
Buildings & Infrastructure
Market structure
Oligopoly
Competitive
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
64 / 100
66 / 100
Moat domains
Demand, Legal, Supply
Legal, Supply, Demand
Last update
2025-12-30
2025-12-28

Moat coverage

Shared moat types

Procurement Inertia

Abbott Laboratories strengths

Brand TrustInstalled Base ConsumablesData Workflow LockinGovernment Contracting RelationshipsCompliance AdvantageDistribution ControlScale Economies Unit CostTraining Org Change CostsIP Choke Point

Bureau Veritas S.A. strengths

Regulated Standards PipeService Field NetworkOperational ExcellenceSwitching Costs GeneralCapex Knowhow Scale

Segment mix

Abbott Laboratories segments

Full profile >

Established Pharmaceutical Products

Competitive

12.4%

Diagnostic Products

Oligopoly

22.3%

Pediatric Nutrition

Oligopoly

9.6%

Adult Nutrition

Oligopoly

10.5%

Diabetes Care (CGM & glucose monitoring)

Duopoly

16.2%

Cardiovascular & Electrophysiology Devices

Oligopoly

26.7%

Neuromodulation Devices

Oligopoly

2.3%

Bureau Veritas S.A. segments

Full profile >

Marine & Offshore

Oligopoly

8.1%

Agri-Food & Commodities

Competitive

20.3%

Industry

Competitive

21.1%

Buildings & Infrastructure

Competitive

29.3%

Certification

Competitive

8.4%

Consumer Products Services

Competitive

12.8%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.